Life Sciences & Biotechnology
Title : | Synchronizing In-silico, In-vitro and In-vivo Approaches for the Development of Oral Mups of Berberine Loaded Lipid Nanocarrier for Amerlioration of Chemotherapy Induced Mucositis |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Varsha B Pokharkar, Poona College Of Pharmacy, Pune, Maharashtra |
Timeline Start Year : | 2022 |
Timeline End Year : | 2025 |
Contact info : | varsha.pokharkar@bharatividyapeeth.edu |
Equipments : | High speed centrifuge |
Details
Executive Summary : | Chemotherapy-induced gastrointestinal mucositis (IM) is a common side effect of drugs like cytarabine, 5-fluorouracil (5FU), alkylating agents, and platinum-based compounds. It involves cell injury, DNA damage, reactive oxygen species generation, inflammatory pathways activation, and increased cytokines and oxidative stress levels. IM significantly impacts patients' quality of life and treatment outcomes. Despite its clinical importance, there is no curative treatment for IM. A proposed project aims to address this issue through an integrated approach that utilizes in silico, in vitro, and in vivo studies for the development of an oral multiparticulate system (MUPS) for Berberine (BER). Berberine, an isoquinoline alkaloid from plants like Tinospora cordifolia and Berberis aristata, has anti-inflammatory potential and inhibits several inflammatory pathways. It is hypothesized that BER when co-administered with chemotherapeutic agents may prevent or alleviate IM. The project will strategize to establish evidence by synchronizing the in-silico, in vitro, and in vivo approaches. The first step will be gathering information on the binding strength interaction between Berberine and mucositis/inflammation-related protein targets. The multi-particulate formulation for oral delivery of BER will be developed, improving solubility and permeability using a suitable lipid-based carrier system. The selection of a suitable lipid-based carrier will be based on a systematic in-silico approach to identify functional lipid excipients with synergistic activity and able to accommodate a high payload of BER. The administration of BER-MUPS alongside chemotherapy is expected to reduce the extent and intensity of intestinal mucositis caused by chemotherapy, providing a clinical benefit to cancer patients. |
Co-PI: | Dr. Arulmozhi Sathiyanarayanan, Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy, Pune, Maharashtra-411038 |
Total Budget (INR): | 29,90,900 |
Organizations involved